Study Prompts Patients To Question Whether They Should Continue Use Of Vytorin
Patients have begun “swamping” physician offices to ask whether they should end treatment with the cholesterol medication Vytorin, co-marketed by Merck and
More: continued here
Filed under: Cholesterol on January 29th, 2008